{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:37:58Z","timestamp":1792467478419,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ejpn-journal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ejpn.2024.05.004","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T07:15:47Z","timestamp":1715843747000},"page":"24-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The when, why, and how of using glycopyrronium to diminish drooling in children with neurodevelopmental disabilities: Implications for clinical practice"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0561-4768","authenticated-orcid":false,"given":"Lynn B.","family":"Orri\u00ebns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.W.","family":"van der Burg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.A.","family":"van den Hoogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7860-7791","authenticated-orcid":false,"given":"Mich\u00e8l A.A.P.","family":"Willemsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9456-3450","authenticated-orcid":false,"given":"Karen","family":"van Hulst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6657-941X","authenticated-orcid":false,"given":"Corrie E.","family":"Erasmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2024.05.004_bib1","series-title":"Glycopyrrolate Treasure Island (FL): StatPearls Publishing","author":"Gallanosa","year":"2020"},{"issue":"1","key":"10.1016\/j.ejpn.2024.05.004_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4103\/0975-8844.113684","article-title":"Adverse affects of drugs on saliva and salivary glands","volume":"5","author":"Vinayak","year":"2013","journal-title":"J.\u00a0Orofac. Sci."},{"key":"10.1016\/j.ejpn.2024.05.004_bib3","series-title":"Cerebral Palsy in under 25s: Assessment and Management","year":"2017"},{"key":"10.1016\/j.ejpn.2024.05.004_bib4","series-title":"AACPDM Care Pathway for Sialorrhea in Cerebral Palsy","author":"Glader","year":"2017"},{"issue":"1","key":"10.1016\/j.ejpn.2024.05.004_bib5","article-title":"Management of drooling of saliva","volume":"5","author":"Bavikatte","year":"2012","journal-title":"Br. J. Med. Pract."},{"key":"10.1016\/j.ejpn.2024.05.004_bib6","series-title":"Glycopyrronium Bromide (Sialanar\u00ae) for the Symptomatic Treatment of Severe Sialorrhoea","year":"2019"},{"issue":"12","key":"10.1016\/j.ejpn.2024.05.004_bib7","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/archpedi.154.12.1214","article-title":"Treatment of sialorrhea with glycopyrrolate: a double-blind, dose-ranging study","volume":"154","author":"Mier","year":"2000","journal-title":"Arch. Pediatr. Adolesc. Med."},{"issue":"4","key":"10.1016\/j.ejpn.2024.05.004_bib8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1136\/archdischild-2017-313763","article-title":"Drooling Reduction Intervention randomised trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability","volume":"103","author":"Parr","year":"2018","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ejpn.2024.05.004_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/TCRM.S26893","article-title":"Randomized Phase III evaluation of the efficacy and safety of a novel glycopyrrolate oral solution for the management of chronic severe drooling in children with cerebral palsy or other neurologic conditions","volume":"8","author":"Zeller","year":"2012","journal-title":"Therapeut. Clin. Risk Manag."},{"issue":"9","key":"10.1016\/j.ejpn.2024.05.004_bib10","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/archpedi.1996.02170340046009","article-title":"Glycopyrrolate treatment of chronic drooling","volume":"150","author":"Blasco","year":"1996","journal-title":"Arch. Pediatr. Adolesc. Med."},{"issue":"3","key":"10.1016\/j.ejpn.2024.05.004_bib11","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/dmcn.14350","article-title":"Anticholinergic medications for reducing drooling in children with developmental disability","volume":"62","author":"Reid","year":"2020","journal-title":"Dev. Med. Child Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2024.05.004_bib12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1440-1754.1997.tb00991.x","article-title":"Preliminary study of glycopyrrolate in the management of drooling","volume":"33","author":"Stern","year":"1997","journal-title":"J.\u00a0Paediatr. Child Health"},{"key":"10.1016\/j.ejpn.2024.05.004_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/TCRM.S27362","article-title":"Safety and efficacy of glycopyrrolate oral solution for management of pathologic drooling in pediatric patients with cerebral palsy and other neurologic conditions","volume":"8","author":"Zeller","year":"2012","journal-title":"Therapeut. Clin. Risk Manag."},{"issue":"8","key":"10.1016\/j.ejpn.2024.05.004_bib14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/000992289803700805","article-title":"Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy","volume":"37","author":"Bachrach","year":"1998","journal-title":"Clin. Pediatr."},{"key":"10.1016\/j.ejpn.2024.05.004_bib15","series-title":"EPAR - Product Information","year":"2016"},{"issue":"Suppl 2","key":"10.1016\/j.ejpn.2024.05.004_bib16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1468-1331.2010.03131.x","article-title":"Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement","volume":"17","author":"Reddihough","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2024.05.004_bib17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/01.mrr.0000194395.64396.f1","article-title":"Drooling in children with cerebral palsy: a qualitative method to evaluate parental perceptions of its impact on daily life, social interaction, and self-esteem","volume":"29","author":"van der Burg","year":"2006","journal-title":"Int. J. Rehabil. Res."},{"key":"10.1016\/j.ejpn.2024.05.004_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/dmcn.14888","article-title":"Posterior drooling in children with cerebral palsy and other neurodevelopmental disorders","author":"Delsing","year":"2021","journal-title":"Dev. Med. Child Neurol."},{"issue":"7","key":"10.1016\/j.ejpn.2024.05.004_bib19","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry"},{"key":"10.1016\/j.ejpn.2024.05.004_bib20","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000012573","article-title":"Placebo-controlled clinical trial of incobotulinumtoxinA for sialorrhea in children: SIPEXI","author":"Berweck","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ejpn.2024.05.004_bib21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/01616412.2020.1820698","article-title":"The impact of botulinum toxin type A in the treatment of drooling in children with cerebral palsy secondary to Congenital Zika Syndrome: an observational study","volume":"43","author":"Sales","year":"2021","journal-title":"Neurol. Res."},{"issue":"3","key":"10.1016\/j.ejpn.2024.05.004_bib23","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/dmcn.14391","article-title":"Changes in severity and impact of drooling after submandibular gland botulinum neurotoxin A injections in children with neurodevelopmental disabilities","volume":"62","author":"van Hulst","year":"2020","journal-title":"Dev. Med. Child Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2024.05.004_bib24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.12965\/jer.150199","article-title":"Difference, significant difference and clinically meaningful difference: the meaning of change in rehabilitation","volume":"11","author":"Dvir","year":"2015","journal-title":"J.\u00a0Exerc. Rehabil."},{"issue":"12","key":"10.1016\/j.ejpn.2024.05.004_bib25","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/dmcn.14673","article-title":"How do we know if interventions in developmental disability are effective?","volume":"62","author":"Rosenbaum","year":"2020","journal-title":"Dev. Med. Child Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2024.05.004_bib26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.0045-0766.2001.00273.x","article-title":"Towards family-centred practice in paediatric occupational therapy: a review of the literature on parent\u2013therapist collaboration","volume":"49","author":"Hanna","year":"2002","journal-title":"Aust. Occup. Ther. J."},{"key":"10.1016\/j.ejpn.2024.05.004_bib27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ijporl.2018.10.035","article-title":"Sialorrhea & aspiration control - a minimally invasive strategy uncomplicated by anticholinergic drug tolerance or tachyphylaxis","volume":"116","author":"Dohar","year":"2019","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"issue":"2","key":"10.1016\/j.ejpn.2024.05.004_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.208","article-title":"The nocebo effect of drugs","volume":"4","author":"Plan\u00e8s","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"issue":"7538","key":"10.1016\/j.ejpn.2024.05.004_bib29","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/bmj.38726.603310.55","article-title":"Sham device v inert pill: randomised controlled trial of two placebo treatments","volume":"332","author":"Kaptchuk","year":"2006","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ejpn.2024.05.004_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40271-018-0336-2","article-title":"Parent empowerment in pediatric healthcare settings: a systematic review of observational studies","volume":"12","author":"Ashcraft","year":"2019","journal-title":"The Patient"},{"issue":"11","key":"10.1016\/j.ejpn.2024.05.004_bib31","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1469-8749.2002.tb00286.x","article-title":"Management of drooling: 10 years after the consortium on drooling, 1990","volume":"44","author":"Blasco","year":"2002","journal-title":"Dev. Med. Child Neurol."},{"issue":"3","key":"10.1016\/j.ejpn.2024.05.004_bib32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bjc.2013.725","article-title":"Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence","volume":"110","author":"Booth","year":"2014","journal-title":"Br. J. Cancer"}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109037982400062X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109037982400062X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T04:56:55Z","timestamp":1721883415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109037982400062X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":31,"alternative-id":["S109037982400062X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2024.05.004","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The when, why, and how of using glycopyrronium to diminish drooling in children with neurodevelopmental disabilities: Implications for clinical practice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2024.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}